Skip to search formSkip to main contentSkip to account menu

MKC-1

An orally bioavailable, small-molecule, bisindolylmaleimide cell cycle inhibitor with potential antineoplastic activity. MKC-1 and its metabolites… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
5577 Background: MKC-1 is a novel oral cell cycle inhibitor with preclinical activity in xenograft models of human ovarian and… 
2016
2016
The research was a development model in teaching of creative writing short story based siri’na pace. The purpose of this study… 
2012
2012
SummaryBackground MKC-1 is an orally available cell cycle inhibitor with downstream targets that include tubulin and the importin… 
2010
2010
e13001 Background: MKC-1 is an oral cell-cycle inhibitor amenable to a variety of dosing schedules. Previous clinical trials used… 
2009
2009
e19005 Background: MKC-1 is a novel oral cell cycle inhibitor with preclinical activity against NSCLC cell lines including multi… 
2008
2008
1046 Background: MKC-1 is a novel oral cell cycle inhibitor with in vitro and in vivo activity against many tumor cell lines… 
2008
2008
19052 Background: MKC-1 is a novel oral cell cycle inhibitor with in vitro and in vivo activity against many tumor cell lines… 
2007
2007
11508 Background: MKC-1 (previously Ro 31–7453) is a novel cell cycle inhibitor with significant in vitro and in vivo activity… 
2007
2007
B290 MKC-1 (previously Ro 31-7453) is a novel, orally active cell cycle inhibitor with significant in vitro and in vivo activity… 
2006
2006
MKC-1 is a novel, orally active cell cycle inhibitor with in vitro and in vivo activity against a wide range of human solid tumor…